Discount banner b26cfd0bc994d525c830a167ad93d0c19724a63776637770540876f8c5116b58
Biomarker Test Market Research Report- Global Forecast to 2022

Biomarker Test Market Research Report- Global Forecast to 2022

ID: MRFR/LS/2428-CRR | April, 2017 | Region: Global | 82 pages | Cooked Research Reports

Global Biomarker Test Market Information, by application (Cancer, Cardiovascular, Infectious Diseases, Central Nervous System, Others by End User (Pharma & Biotech Companies, Diagnostic tool companies, Healthcare IT/Big data companies, Clinical laboratories) - Forecast to 2022


Market Synopsis of Global Biomarker Test Market:


Market Scenario:


Most healthcare professionals use diagnosis tests to clarify and support their clinical decision making. Progressively over recent years, the analytic procedure has turned out to be stronger by the need to preselect patients in light of medications and licenses. This move has come to through various factors, which incorporate propelling technology (empowering professionals to measure more particular markers of adequacy), an increased comprehension of the disease procedure, and a more prominent energy about the uniqueness of an individual's tumour at the molecular level. These components are reflected in the changing outline of clinical trials. But this move is driven by societal elements as well as, most noticeable among which is the need to limit targeted therapies to those patients destined to benefit. With the appearance of customized/precision prescription, the one-estimate fits-all approach is being consigned to history of life science.. 


The global market for Biomarker test is expected to reach USD 16,112.8 million by the end of the forecasted period 2016-2022 and is expected to grow at a CAGR of 14.5%.


Study Objectives Global Biomarker Test Market:



  • To provide detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the Global Biomarker test Market

  • To provide insights about factors affecting the market growth

  • To analyze the market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size, volume, average selling price and future prospective

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments globally


Global Biomarker Test Market, by Application, 2015 (%):
Biomarker test Market, by Application


 


Intended Audience



  • Biomarker test device Manufacturer

  • Biomarker test device Vendors

  • Private Research Laboratories

  • Pharmaceutical & Biotechnology Companies

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories


Key Finding



  • The global Biomarker test market and is expected to reach USD 16,112.8 million by 2022.

  • On the basis of application, cancer holds the largest market share of global Biomarker test market and is expected to reach USD 5,395.6 million by 2022.

  • By end users, Pharma & Biotech companies holds the largest market share of global Biomarker test market is expected to reach USD 5,451.8 million by 2022.


Key Players for Global Biomarker Test Market:


Some of the key players in this market are: F. Hoffmann-La Roche AG, Novartis AG, PFIZER INC., GlaxoSmithKline plc., GE Healthcare, Medtronics, Quest Diagnostics and others.


Segments:


Global Biomarker test Market has been segmented on the basis of application which comprises of Cancer, Cardiovascular, Infectious Diseases, Central Nervous System. On the basis of end users which includes Pharma & Biotech Companies, Diagnostic tool companies, Healthcare IT/Big data companies, Clinical laboratories.


Regional Analysis of Global Biomarker Test Market:


The global market for Biomarker test is growing rapidly. The market for Biomarker test is growing with the CAGR of 14.5% during the forecast period from 2016-2022. North America accounts for largest market share in 2015 and is expected to reach USD 6,640.4 million by 2022.


Asia-Pacific region is the fastest growing market for Biomarker test, which is expected to grow at a CAGR of 15.2% during the forecast period from 2016 to 2022.   

The report for Global Biomarker test Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions

License
Single User Enterprise User (Buy Premium Reports Chapterwise)
Currency
TABLE OF CONTENTS

1.1 Introduction
1.2 FDA Regulations

2.1 Introduction
2.2 Research Objective
2.3 Assumptions & Limitations
2.3.1 Assumptions
2.3.2 Limitations
2.4 Market Structure

3.1 Primary Research
3.2 Secondary Research

4.1 Porters Five Forces
4.1.1 Bargaining Power of Suppliers
4.1.2 Bargaining Power of Buyer
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Intensity of Rivalry
4.2 Value Chain
4.2.1 Device Manufacturer & Drug Producers
4.2.2 Healthcare Providers
4.2.3 Healthcare ITs or big data companies
4.2.4 Regulators
4.2.5 Third party payers
4.2.6 Patients

5.1 Introduction
5.2 Drivers
5.2.1 Involvement of patients in personal healthcare
5.2.2 Demand for biomarkers in other technologies like next-generation sequencing technologies, ultra-high throughput sequencing.
5.2.3 Growing Prevalence of Genetic Diseases
5.2.4 Growing Potential for biomarkers in targeted therapies
5.3 Restrains
5.3.1 Lack of Awareness About The Possible Applications of Biomarkers
5.3.2 Regulatory Framework
5.3.3 Lack of Research and Indications Creating Difficulties in the Application
5.4 Opportunities
5.4.1 Introduction of Biomarkers in Developing Nations

6.1 Cancer Application
6.2 Cardiovascular Application
6.3 Infectious Diseases Application
6.4 Central Nervous System Application
6.5 Others Applications

7.1 Pharma & Biotech Companies
7.2 Diagnostic Tool Companies
7.3 Healthcare IT/Big Data Companies
7.4 Clinical Laboratories

8.1 North America
8.1.1 US
8.1.2 Canada
8.2 Europe
8.2.1 Germany
8.2.2 France
8.2.3 UK
8.2.4 Italy
8.2.5 Spain
8.2.6 Rest of Europe
8.3 Asia Pacific
8.3.1 Japan
8.3.2 China
8.3.3 India
8.3.4 Republic of Korea
8.3.5 Australia
8.3.6 Rest of Asia Pacific
8.4 Middle East & Africa
8.4.1 UAE
8.4.2 Saudi Arabia
8.4.3 Egypt
8.4.4 Rest of Middle & Africa

10.1 F. Hoffmann-La Roche AG
10.1.1 Overview
10.1.2 Product/Business Segment Overview
10.1.3 Financial Updates
10.1.4 Key Developments
10.1.5 SWOT Analysis
10.2 Novartis AG
10.2.1 Overview
10.2.2 Product/Business Segment Overview
10.2.3 Financial Updates
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Pfizer Inc.
10.3.1 Overview
10.3.2 Product/Business Segment Overview
10.3.3 Financial Updates
10.3.4 Key Developments
10.3.5 SWOT Analysis
10.4 GlaxoSmithKline plc.
10.4.1 Company Overview
10.4.2 Product overview
10.4.3 Financial Overview
10.4.4 Key Development
10.4.5 SWOT Analysis
10.5 GE Healthcare
10.5.1 Company Overview
10.5.2 Product/Business Segment Overview
10.5.3 Financial Overview
10.5.4 Key Development
10.5.5 SWOT Analysis
10.6 Medtronics
10.6.1 Company Overview
10.6.2 Product/Business Segment Overview
10.6.3 Financial Overview
10.6.4 Key Development
10.7 Quest Diagnostics
10.7.1 Company Overview
10.7.2 Product Overview
10.7.3 Financial Overview
10.7.4 Key Developments

TABLE 1CANCER BIOMARKERS FOR WHICH TESTING IS MANDATED BY THE FDA PRIOR TO USE OF THE DRUG11
TABLE 2GLOBAL BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2014-2022)25
TABLE 3GLOBAL BIOMARKER TEST MARKET, BY CANCER APPLICATION US$ MILLION (2014-2022)26
TABLE 4GLOBAL BIOMARKER TEST MARKET, BY CARDIOVASCULAR APPLICATION US$ MILLION (2014-2022)26
TABLE 5GLOBAL BIOMARKER TEST MARKET, BY INFECTIOUS DISEASES APPLICATION US$ MILLION (2014-2022)27
TABLE 6GLOBAL BIOMARKER TEST MARKET, BY CENTRAL NERVOUS SYSTEM APPLICATION US$ MILLION
(2014-2022)27
TABLE 7GLOBAL BIOMARKER TEST MARKET, BY OTHERS APPLICATION US$ MILLION (2014-2022)28
TABLE 8GLOBAL BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022)29
TABLE 9GLOBAL BIOMARKER TEST MARKET, BY PHARMA & BIOTECH COMPANIES US$ MILLION (2014-2022)30
TABLE 10GLOBAL BIOMARKER TEST MARKET, BY DIAGNOSTIC TOOL COMPANIES END USER US$ MILLION (2014-2022)30
TABLE 11GLOBAL BIOMARKER TEST MARKET, BY HEALTHCARE IT/BIG DATA COMPANIES END USER US$ MILLION (2014-2022)31
TABLE 12GLOBAL BIOMARKER TEST MARKET, BY CLINICAL LABORATORIES END USER US$ MILLION (2014-2022)31
TABLE 13GLOBAL BIOMARKER TESTS MARKET, BY REGION US$ MILLION (2014-2022)32
TABLE 14NORTH AMERICA BIOMARKER TESTS MARKET, BY COUNTRY US$ MILLION (2014-2022)33
TABLE 15NORTH AMERICA BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2014-2022)34
TABLE 16NORTH AMERICA BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022)34
TABLE 17US BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2014-2022)35
TABLE 18US BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022)35
TABLE 19CANADA BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2014-2022)36
TABLE 20CANADA BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022)36
TABLE 21EUROPE BIOMARKER TESTS MARKET, BY COUNTRY US$ MILLION (2014-2022)37
TABLE 22EUROPE BIOMARKER TESTS MARKET, BY APPLICATION BY APPLICATION US$ MILLION (2014-2022)38
TABLE 23EUROPE BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022)38
TABLE 24GERMANY BIOMARKER TESTS MARKET, BY APPLICATION BY APPLICATION US$ MILLION (2014-2022)39
TABLE 25GERMANY BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022)39
TABLE 26FRANCE BIOMARKER TESTS MARKET, BY APPLICATION BY APPLICATION US$ MILLION (2014-2022)40
TABLE 27FRANCE BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022)40
TABLE 28UK BIOMARKER TESTS MARKET, BY APPLICATION BY APPLICATION US$ MILLION (2014-2022)41
TABLE 29UK BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022)41
TABLE 30ITALY BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2014-2022)42
TABLE 31ITALY BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022)42
TABLE 32SPAIN BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2014-2022)43
TABLE 33SPAIN BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022)43
TABLE 34REST OF EUROPE BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2014-2022)44
TABLE 35REST OF EUROPE BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022)44
TABLE 36ASIA PACIFIC BIOMARKER TESTS MARKET BY, COUNTRY US$ MILLION (2014-2022)45
TABLE 37ASIA PACIFIC BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2014-2022)46
TABLE 38ASIA PACIFIC BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022)46
TABLE 39JAPAN BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2014-2022)47
TABLE 40JAPAN BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022)47
TABLE 41CHINA BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2014-2022)48
TABLE 42CHINA BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022)48
TABLE 43INDIA BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2014-2022)49
TABLE 44INDIA BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022) 49
TABLE 45REPUBLIC OF KOREA BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2014-202250
TABLE 46REPUBLIC OF KOREA BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022) 50
TABLE 47AUSTRALIA BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2014-2022) 51
TABLE 48AUSTRALIA BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022) 51
TABLE 49REST OF ASIA PACIFIC BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2014-2022) 52
TABLE 50REST OF ASIA PACIFIC BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022) 52
TABLE 51MIDDLE EAST & AFRICA BIOMARKER TESTS MARKET BY, COUNTRY US$ MILLION (2014-2022) 53
TABLE 52MIDDLE EAST & AFRICA BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2014-2022) 54
TABLE 53MIDDLE EAST & AFRICA BIOMARKER TESTS MARKET, BY END USER US$ MILLION (2014-2022) 54
TABLE 54UAE BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2014-2022) 55
TABLE 55UAE BIOMARKER TESTS MARKET, BY END USER US$ MILLION (2014-2022) 55
TABLE 56SAUDI ARABIA BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2014-2022) 56
TABLE 57SAUDI ARABIA BIOMARKER TESTS MARKET, BY END USER US$ MILLION (2014-2022) 56
TABLE 58EGYPT BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2014-2022) 57
TABLE 59EGYPT BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022) 57
TABLE 60REST OF MIDDLE & AFRICA BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2014-2022) 58
TABLE 61REST OF MIDDLE & AFRICA BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2014-2022) 58
TABLE 62GE HEALTHCARE: KEY DEVELOPMENT 73
TABLE 63MEDTRONICS: KEY DEVELOPMENT 76

 

FIGURE 1REGULATORY PATHWAY OPTION FOR DIAGNOSTICS 12
FIGURE 2RESEARCH PROCESS 15
FIGURE 3GLOBAL BIOMARKER TESTS MARKET, BY APPLICATION US$ MILLION (2015-2022) 25
FIGURE 4GLOBAL BIOMARKER TESTS MARKET, BY END USERS US$ MILLION (2015-2022) 29
FIGURE 5GLOBAL BIOMARKER TESTS MARKET, BY REGION US$ MILLION (2015-2022) 32
FIGURE 6NORTH AMERICA BIOMARKER TESTS MARKET, BY COUNTRY MARKET SHARE 2015 (%) 33
FIGURE 7EUROPE BIOMARKER TESTS MARKET, BY COUNTRY MARKET SHARE 2015 (%) 37
FIGURE 8ASIA PACIFIC BIOMARKER TESTS MARKET BY, COUNTRY MARKET SHARE 2015 (%) 45
FIGURE 9MIDDLE EAST & AFRICA BIOMARKER TESTS MARKET BY, COUNTRY MARKET SHARE 2015 (%) 53
FIGURE 10GLOBAL BIOMARKER TEST COMPETITIVE ANALYSIS (%) 59
FIGURE 11F. HOFFMANN-LA ROCHE AG: FINANCIAL REVENUE 61
FIGURE 12F. HOFFMANN-LA ROCHE AG: SEGMENTAL REVENUE 61
FIGURE 13NOVARTIS FINANCIAL DATA: REVENUE AND R&D 64
FIGURE 14NOVARTIS FINANCIAL DATA: SEGMENTAL REVENUE 64
FIGURE 15NOVARTIS FINANCIAL DATA: GEOGRAPHICAL REVENUE 64
FIGURE 16PFIZER FINANCIAL DATA: REVENUE AND R&D 66
FIGURE 17PFIZER FINANCIAL DATA SEGMENTAL REVENUE 67
FIGURE 18PFIZER FINANCIAL DATA GEOGRAPHICAL REVENUE 67
FIGURE 19GLOAXOSMITHKLINE: RECENT FINANCIAL 69
FIGURE 20GLAXOSMITHKLINE: OPERATING SEGMENTS 70
FIGURE 21GLAXOSMITHKLINE: GEOGRAPHICAL MIX 70
FIGURE 22GE HEALTHCARE: RECENT FINANCIAL 72
FIGURE 23GE HEALTHCARE: OPERATING SEGMENTS 73
FIGURE 24GE HEALTHCARE: GEOGRAPHICAL MIX 73
FIGURE 25MEDTRONICS: RECENT FINANCIAL 75
FIGURE 26MEDTRONICS: OPERATING SEGMENTS 76
FIGURE 27MEDTRONICS: GEOGRAPHICAL MIX 76
FIGURE 28QUEST DIAGNOSTICS: OPERATING INCOME 78
FIGURE 29QUEST DIAGNOSTICS: SEGMENTAL REVENUE79